Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 19/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.67 |
| ▸ | HRH2 | P25021 | 4/20 | 0.60 |
| ▸ | HTR2C | P28335 | 4/20 | 0.60 |
| ▸ | HRH1 | P35367 | 4/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | HTR1A | P08908 | 3/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 3/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.60 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | HTR5A | P47898 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 3/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30031624 | 0.95 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL18530311 | 0.95 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL31129893 | 0.90 | TMEM97 (0.63) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL7005876 | 0.90 | TMEM97 (0.63) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL1299903 | 0.88 | TMEM97 (0.70) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30515329 | 0.88 | TMEM97 (0.70) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL324228 | 0.86 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL325572 | 0.85 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL1793928 | 0.85 | TMEM97 (0.67) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL24229547 | 0.84 | TMEM97 (0.66) | TMEM97SIGMAR1HRH2HTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210300903-A1 | SIGMA RECEPTOR BINDERS | UNIV TEXAS (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300903-A1 | SIGMA RECEPTOR BINDERS | UNIV TEXAS (US) | 2021-09-30 | — | — | US | disclosed |
| US-10954217-B2 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-23 | — | — | US | disclosed |
| US-10954217-B2 | Sigma receptor binders | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-23 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3623369-A1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2020-03-18 | — | — | EP | disclosed |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-06-13 | — | — | US | disclosed |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-06-13 | — | — | US | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017190109-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017190109-A1 | SIGMA RECEPTOR BINDERS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-02 | — | — | WO | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-1501803-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | TMEM97 1582/4885SIGMAR1 2841/4885HRH2 238/4885 |
| US-10954217-B2 | Sigma receptor binders | SIGMAR1, OPRK1, OPRL1 | TMEM97 6/4885SIGMAR1 1/4885HRH2 486/4885 |
| US-20190177301-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | TMEM97 6/4885SIGMAR1 1/4885HRH2 486/4885 |
| US-20210300903-A1 | SIGMA RECEPTOR BINDERS | SIGMAR1, OPRK1, OPRL1 | TMEM97 6/4885SIGMAR1 1/4885HRH2 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.